Deals & Corporate Governance

  • January 16, 2024

    Therapy Co. Says Ex-Directors 'Raided' Staff And Patients

    Two psychotherapists who resigned from their roles as directors of a Pennsylvania-based mental health practice have been hit with a suit alleging they "brazenly solicited and raided" workers from the practice to launch their own therapy business.

  • January 16, 2024

    Union Funds Drop Suit Against CIA Janitorial Contractors

    Two union benefit funds have dropped their federal lawsuit against a pair of companies that staff janitorial workers and security guards at the Central Intelligence Agency's headquarters, agreeing in a stipulation of dismissal docketed Tuesday to stop pursuing claims that the companies withheld financial documents from fund-retained auditors.

  • January 16, 2024

    Crowell Adds Moses Singer Health Trio In New NYC Office

    Crowell & Moring LLP announced Tuesday that it has hired a team from Moses & Singer LLP with rare expertise in regulatory and compliance issues related to clinical trials for biotech and health tech companies.

  • January 12, 2024

    UPenn Health System Eyes Merger With Ailing Hospital

    The University of Pennsylvania Health System has announced plans to acquire Doylestown Health in a deal that aims to increase its competitive footprint in the Philadelphia area.

  • January 12, 2024

    Taxation With Representation: Kirkland, Latham, Wachtell

    In this week's Taxation With Representation, Chesapeake Energy and Southwestern Energy announce a merger, Hewlett Packard Enterprise acquires Juniper Networks, Johnson & Johnson buys Ambrx Biopharma Inc., and Boston Scientific Corp. purchases Axonics Inc.

  • January 11, 2024

    2nd Circ. Hears UnitedHealth Office-Based Surgery Fight

    A Second Circuit panel was told Thursday that a lower court erred when it found UnitedHealth Group Inc. and related companies didn't violate federal benefits law by not paying facility fees to out-of-network, office-based surgery providers.

  • January 11, 2024

    Wash. Justice Flags Class Action 'Weakness' In Wage Claim

    Washington's high court debated Thursday whether U.S. Supreme Court precedent on class actions required the revival of a nurse's wage-theft suit, with one justice noting a "weakness" in the case because it was not itself a class action.

  • January 11, 2024

    Activist Firm Sets Off Board Challenge At Healthcare REIT

    Hedge fund Land & Buildings Investment Management LLC has nominated three candidates to healthcare real estate investment trust Ventas Inc.'s board of directors, the REIT said Thursday, which kicks off a fight for power at a company Land & Buildings has leveled criticism at for over two years.

  • January 11, 2024

    Medtech Co. Integer To Buy Pulse Technologies For $140M

    Medical device manufacturer Integer Holdings Corp. announced Wednesday that it has acquired private engineering and contract manufacturing company Pulse Technologies Inc. for around $140 million.

  • January 10, 2024

    Union Funds Exit Amgen, Teva Antitrust MDL

    Teva Pharmaceuticals has settled its differences with the union funds making up the indirect purchase class in multidistrict litigation accusing it of hatching an illegal deal to remove a generic calcium-control drug from the market.

  • January 10, 2024

    US Trustee Calls SmileDirect Ch. 11 Deal An Improper Plan

    The Office of the United States Trustee objected Wednesday to a global settlement proposed by bankrupt teledentistry company SmileDirectClub Inc., saying it amounts to an impermissible sub rosa plan that wouldn't cover the administrative costs of the Chapter 11 case prior to its dismissal.

  • January 10, 2024

    CNS Startup Myrobalan Therapeutics Raises $24M Series A

    Biotech company Myrobalan Therapeutics announced Wednesday it has raised a $24 million series A to develop treatments for degenerative CNS conditions.

  • January 09, 2024

    FTC Blocked IQVIA On Old Threshold, Without 'Rubber Stamp'

    The judge who temporarily blocked the merger between healthcare data company IQVIA and Propel Media shortly before it was abandoned insisted in his newly published federal court ruling that his decision wasn't a "rubber stamp" of the Federal Trade Commission's request to halt the deal.

  • January 09, 2024

    VC Firm Expands Collaborations In New Tech Initiative Debut

    Biotech venture capital firm Flagship Pioneering announced expanded collaborations with Samsung C&T Corp. and Thermo Fisher Scientific Inc. on Monday, as part of a larger initiative focused on fostering "enabling technologies" for the life sciences, during the J.P. Morgan Healthcare Conference in San Francisco.

  • January 09, 2024

    Biopharma Co. Can't Dodge Secrets Row Over Detox Drug

    A Florida federal judge has refused to throw out a suit from GBB Drink Lab Inc. claiming FSD Biosciences flouted a nondisclosure agreement relating to a blood-alcohol detoxification product.

  • January 09, 2024

    GSK Agrees To Buy US Respiratory Drug Biz For Up To $1.4B

    GSK said Tuesday that it has agreed to buy Aiolos Bio Inc., a clinical-stage asthma drug developer, in a deal that could reach $1.4 billion as the British pharmaceuticals giant looks to grow its portfolio of respiratory treatments.

  • January 08, 2024

    Merck Lands Cancer Fighter Harpoon Therapeutics For $680M

    Merck has entered into an agreement to acquire Harpoon Therapeutics, a cancer immunotherapy company founded eight years ago, for $23 per share in cash for an approximate total equity value of $680 million, the companies said Monday.

  • January 08, 2024

    Novartis To Buy Merck Spin-Off Calypso Biotech For Up To $375M

    Swiss pharmaceutical giant Novartis is buying European company Calypso Biotech in a deal that could be worth up to $375 million, according to an announcement from Calypso on Monday, marking one of the earliest deals to be announced at the start of the deal frenzy expected at the J.P. Morgan Healthcare conference in San Francisco this week.

  • January 08, 2024

    Eli Lilly, Novartis Could Pump Close To $3B Into AI Drug Tech

    Eli Lilly & Co. and Novartis could invest close to $3 billion in the development of artificial intelligence for drug discovery under two new agreements with a digital biology company owned by Google's parent company.

  • January 08, 2024

    Cravath Steers J&J Buy Of Skadden-Led Ambrx In $2B Deal

    Pharmaceutical industry giant Johnson & Johnson, advised by Cravath Swaine & Moore LLP, is buying San Diego, California-based clinical-stage biopharmaceutical company Ambrx Biopharma Inc., advised by Skadden Arps Slate Meagher & Flom LLP, in an all-cash, take-private deal with a total equity value of roughly $2 billion, the two companies announced separately Monday.

  • January 05, 2024

    Pharma Co. Snags $100M To Advance Psychedelic Treatment

    The pharmaceutical arm of the nonprofit Multidisciplinary Association for Psychedelic Studies said on Friday it raised $100 million in an initial round of financing as it transitions to new leadership.

  • January 05, 2024

    ​​Boehringer Ingelheim Inks €410M Deal With Kyowa Kirin

    Pharmaceutical giant Boehringer Ingelheim announced Friday that it had entered into a €410 million ($449 million) licensing agreement with Japanese pharmaceutical company Kyowa Kirin to develop a new treatment for fibro-inflammatory diseases, the third in a string of consecutive deals Boehringer Ingelheim has announced this week.

  • January 05, 2024

    Md. Retirees Ask 4th Circ. For 2nd Shot At Drug Coverage Suit

    Retired Maryland state employees have asked the Fourth Circuit for another chance to pursue a proposed class action over the state's transition of their prescription coverage plan to Medicare Part D after their first try was dismissed last year.

  • January 05, 2024

    9th Circ. Won't Rethink FCA Disclosure Ruling Against Valeant

    A Ninth Circuit panel on Friday denied drugmaker Valeant Pharmaceuticals' request to review its decision to revive a False Claims Act suit accusing Valeant of fraudulently obtaining a patent to extend its monopoly on the drug Apriso.

  • January 05, 2024

    Attys Hopeful For Deals Pickup As JPMorgan Event Kicks Off

    Attorneys heading to the annual J.P. Morgan Healthcare Conference are hoping to strike fruitful conversations with other dealmakers regarding capital-raising and M&A prospects, aided by the backdrop of several blockbuster acquisitions in recent weeks.

Expert Analysis

  • Time For Law Schools To Rethink Unsung Role Of Adjuncts

    Author Photo

    As law schools prepare for the fall 2023 semester, administrators should reevaluate the role of the underappreciated, indispensable adjunct, and consider 16 concrete actions to improve the adjuncts' teaching experience, overall happiness and feeling of belonging, say T. Markus Funk at Perkins Coie, Andrew Boutros at Dechert and Eugene Volokh at UCLA.

  • Tips For In-House Legal Leaders In A Challenging Economy

    Author Photo

    Amid today's economic and geopolitical uncertainty, in-house legal teams are running lean and facing increased scrutiny and unique issues, but can step up and find innovative ways to manage outcomes and capitalize on good business opportunities, says Tim Parilla at LinkSquares.

  • What Associates Need To Know Before Switching Law Firms

    Excerpt from Practical Guidance
    Author Photo

    The days of staying at the same firm for the duration of one's career are mostly a thing of the past as lateral moves by lawyers are commonplace, but there are several obstacles that associates should consider before making a move, say attorneys at HWG.

  • A Case For Sharing Mediation Statements With Counterparties

    Author Photo

    In light of a potential growing mediation trend of only submitting statements to the mediator, litigants should think critically about the pros and cons of exchanging statements with opposing parties as it could boost the chances of reaching a settlement, says Arthur Eidelhoch at Eidelhoch Mediation.

  • Tackling Long-Tail Legacy Liability Risk: A Defendant's Toolkit

    Author Photo

    Johnson & Johnson was recently rebuffed in its efforts to employ the "Texas Two-Step," which is likely to affect this increasingly popular method to isolate and spin off large asbestos and talc liabilities, but companies have multiple options to reduce long-tail legacy liability risk, says Stephen Hoke at Hoke LLC.

  • Challenging Standing In Antitrust Class Actions: Injury-In-Fact

    Author Photo

    As demonstrated in recent cases, the classic injury-in-fact requirement for Article III standing claimed in most antitrust suits is economic harm — and while concrete harm satisfies the requirement, litigants may still be able to challenge whether economic injury has occurred, say Michael Hamburger and Holly Tao at White & Case.

  • Preparing For Legal Scrutiny Of Data Retention Policies

    Author Photo

    Two recent cases involving Google and Meta should serve as a call to action for companies to ensure their data retention policies are updated and properly implemented to the degree of being able to withstand judicial scrutiny, especially as more data is generated by emerging technologies, say Jack Kallus and Labeed Choudhry at Kaufman Dolowich.

  • Congress Must Reform PBMs To Lower The Cost Of Insulin

    Author Photo

    When the U.S. Senate Committee on Health, Education, Labor and Pensions meets Wednesday to ask why insulin prices are increasing, they should follow the money, and work on curtailing the practices of pharmacy benefit managers that inflate drug prices, says David Balto, a former policy director at the Federal Trade Commission.

  • Attorneys Should Have An Ethical Duty To Advance DEI

    Author Photo

    National and state bar associations are encouraging attorneys to apply diversity, equity and inclusion practices in the legal profession and beyond, and these associations should take it one step further by formally recognizing ethical duties for attorneys to promote DEI, which could better the legal profession and society, says Elena Mitchell at Moore & Van Allen.

  • Data-Driven Insights Are Key To Attracting Today's Clients

    Author Photo

    As law firm growth slows and competition for clients increases, modern firms must rely on robust data analytics to develop the sector-based expertise and industry insights that clients increasingly prioritize in relationships with counsel, says Lavinia Calvert at Intapp.

  • Ghosting In BigLaw: Why Better Feedback Habits Are Needed

    Author Photo

    Not giving assignments or constructive criticism to junior associates can significantly affect their performance and hours, potentially leading them to leave the firm, but partners can prevent this by asking the right questions and creating a culture of feedback, says Rachel Patterson at Orrick.

  • Law Needs A Balance Between Humanism And Formalism

    Author Photo

    A recent Law360 guest article rightly questions the pretextual pseudo-originalism that permits ideology to masquerade as judicial philosophy, but the cure would kill the patient because directness, simplicity and humanness are achievable without renouncing form or sacrificing stare decisis, says Vanessa Kubota at the Arizona Court of Appeals.

  • FTC's Criminal Liaison Unit Enhances Merger Risks

    Author Photo

    As it enters its second year, the Criminal Liaison Unit within the Federal Trade Commission’s Bureau of Competition may streamline and sharpen efforts to detect and refer substantive and procedural violations to prosecutors, increasing the chances of a merger review uncovering potential criminal activity, say attorneys at Norton Rose.